AbbVie Inc. extends Rinvoq patent to 2037, delaying generics by 4 years. Rinvoq generated nearly $6 billion in 2024 and is undergoing clinical trials for multiple autoimmune disorders. AbbVie leverages AI for drug development and pipeline management, positioning for growth in immunology and enhancing treatment outcomes with its broad pipeline.

Read more at Yahoo Finance: AbbVie Inc. (ABBV) Extends Rinvoq Patent to 2037, Delaying Generics